New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 23, 2014
06:02 EDTLLYEli Lilly announces EC approval of Jardiance tablets for use in adults
The European Commission granted marketing authorization for Jardiance tablets, a sodium glucose co-transporter 2 inhibitor, for the treatment of type 2 diabetes mellitus to improve glycemic control in adults in Europe, Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly announced. The European Commission approved Jardiance 10 and 25 mg once daily tablets for use when diet and exercise alone do not provide adequate glycemic control. Jardiance may be used alone when metformin is not considered appropriate due to intolerance, or alongside other glucose-lowering medicines including insulin, when glucose control is inadequate.
News For LLY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 3, 2015
08:04 EDTLLYDenovo Biopharma licensed Pomaglumetad Methionil from Eli Lilly
Subscribe for More Information
07:16 EDTLLYCowen to hold a conference
35th Annual Health Care Conference is being held in Boston on March 2-4 with webcasted company presentations to begin on March 3 at 8 am; not all company presentations may be webcasted. Webcast Link
March 2, 2015
08:53 EDTLLYNon-profit gives lukewarm review to MannKind inhaled insulin, TheStreet says
Subscribe for More Information
February 24, 2015
06:34 EDTLLYEli Lilly CEO states company is not for sale, Financial Times says
Subscribe for More Information
February 23, 2015
08:31 EDTLLYEli Lilly announces delay in submission of basal insulin peglispro beyond Q1
Subscribe for More Information
07:06 EDTLLYEli Lilly and Incyte announces positive results for baricitinib
Subscribe for More Information
February 19, 2015
08:04 EDTLLYEli Lilly extends Evacetrapib Phase 3 trial by six months
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use